Merk's experimental pill for covid 19 got a lot of attention over the last week. What we don't have to day amtim is a cheap and effective pill that can be prescribed to people who've contracted cobed. Right now, the treatment landscape is rather barren. But what we really want is something like tamiflet, something that you can take from home,. You don't need to venture too far; it will stop coved in its tracks.
Peter Quigley, President and CEO of Kelly, discusses the jobs September report and employment trends. Bloomberg News U.S. Health Care Reporter Riley Griffin explains how Merck’s Covid pill faces a risk that the virus could outsmart it. Bloomberg News Financial Investigations Reporter Caleb Melby shares his Businessweek Magazine story New York’s Real Estate Tax Breaks Are Now a Rich-Kid Loophole. Dartmouth Professor of Economics Danny Blanchflower talks about seeing a U.S. recession if the history of consumer sentiment repeats. Eric Ervin, CIO at Onramp Invest, breaks down understanding and owning cryptocurrencies. And we Drive to the Close with Alan Lancz, Research Director at www.LanczGlobal.com.
Hosts: Carol Massar and Tim Stenovec. Producer: Paul Brennan.
See omnystudio.com/listener for privacy information.